BNP Paribas Financial Markets Has $28,000 Holdings in PetMed Express, Inc. (NASDAQ:PETS)

BNP Paribas Financial Markets trimmed its stake in PetMed Express, Inc. (NASDAQ:PETS) by 53.4% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,705 shares of the company’s stock after selling 8,812 shares during the period. BNP Paribas Financial Markets’ holdings in PetMed Express were worth $28,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Federated Hermes Inc. increased its position in shares of PetMed Express by 54.5% during the second quarter. Federated Hermes Inc. now owns 606,430 shares of the company’s stock valued at $2,456,000 after purchasing an additional 213,903 shares during the period. Cubist Systematic Strategies LLC acquired a new stake in PetMed Express during the second quarter worth $797,000. Bleakley Financial Group LLC bought a new stake in PetMed Express in the 3rd quarter valued at $279,000. Squarepoint Ops LLC acquired a new position in shares of PetMed Express in the 2nd quarter valued at $273,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of PetMed Express in the 2nd quarter valued at $135,000. Institutional investors own 73.33% of the company’s stock.

Analysts Set New Price Targets

Separately, StockNews.com upgraded shares of PetMed Express from a “hold” rating to a “buy” rating in a research report on Tuesday, November 12th.

PetMed Express Trading Down 2.5 %

Shares of PETS opened at $4.97 on Friday. The stock has a market cap of $102.70 million, a PE ratio of -82.83 and a beta of 0.71. PetMed Express, Inc. has a 1 year low of $2.90 and a 1 year high of $7.79. The stock has a 50 day simple moving average of $4.78 and a 200-day simple moving average of $4.09.

PetMed Express (NASDAQ:PETS) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.11 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.17. The firm had revenue of $59.57 million for the quarter, compared to analysts’ expectations of $66.02 million. PetMed Express had a negative return on equity of 1.00% and a negative net margin of 0.37%. On average, sell-side analysts forecast that PetMed Express, Inc. will post 0.24 EPS for the current fiscal year.

Insider Transactions at PetMed Express

In other news, Director Leslie C.G. Campbell purchased 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 4th. The stock was purchased at an average cost of $5.38 per share, with a total value of $80,700.00. Following the acquisition, the director now directly owns 70,000 shares of the company’s stock, valued at approximately $376,600. This trade represents a 27.27 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 1.10% of the stock is owned by insiders.

About PetMed Express

PetMed Express, Inc, together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and household pet supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.